文献速递肝病

粒细胞集落刺激因子与N-乙酰半胱氨酸治疗重型酒精性肝炎患者的疗效

Efficacy of Granulocyte Colony-Stimulating Factor and N-Acetylcysteine Therapies in Patients With Severe Alcoholic Hepatitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-01-31

一项在印度单中心进行的开放标签随机对照先导研究纳入57例重型酒精性肝炎患者,比较标准治疗(含己酮可可碱)加粒细胞集落刺激因子(G-CSF)、标准治疗加G-CSF与静脉N-乙酰半胱氨酸(NAC)联合治疗、以及单用标准治疗。结果显示G-CSF组和联合组90天生存比例均高于标准治疗组,G-CSF组CD34+细胞增多且改良判别函数评分和终末期肝病模型评分下降更明显,加用NAC未见额外获益。

要点

  • G-CSF组90天生存16/18,联合组13/19,均高于标准治疗组6/20。
  • G-CSF组和联合组第6天CD34+细胞较基线增加,高于标准治疗组。
  • G-CSF组第1、2、3个月改良判别函数评分中位下降分别为60.36%、75.36%、88.73%,高于标准治疗组。

核心结论

  • 在先导性随机对照试验中,与标准治疗相比,G-CSF可改善重型酒精性肝炎患者肝功能并提高生存率。
  • 未发现G-CSF加用NAC有额外获益的证据。
  • 这些发现需在更大规模的试验中确认。

研究设计与样本

  • 开放标签、单中心随机对照先导研究,2014年10月至2017年3月在印度肝脏重症监护病房纳入57例重型酒精性肝炎患者。
  • 患者随机分为G-CSF组(标准治疗含己酮可可碱加G-CSF 5天,n=18)、联合组(标准治疗加G-CSF和静脉NAC 5天,n=19)和标准治疗组(单用标准治疗,n=20)。
  • 主要结局为90天生存患者比例;次要结局包括第6天CD34+细胞动员以及至第90天的Child Turcotte Pugh评分、终末期肝病模型评分和改良判别函数评分。
  • 基线、第6天及研究开始后1、2、3个月收集临床数据和血样,第0天和第6天检测血CD34+细胞。

主要发现

  • G-CSF组90天生存16/18、联合组13/19,均高于标准治疗组6/20(G-CSF组P=0.0001,联合组P=0.037)。
  • G-CSF组和联合组第6天CD34+细胞较基线增加,高于标准治疗组。
  • G-CSF组第1、2、3个月改良判别函数评分中位下降分别为60.36%、75.36%、88.73%,大于标准治疗组(P=0.02、P=0.05、P=0.00);联合组无此显著变化。
  • G-CSF组3个月终末期肝病模型评分中位下降55.77%,大于标准治疗组(P=0.01);Child Turcotte Pugh评分无显著差异。
  • 各组并发症数量相似。

关键数值与推荐

  • G-CSF组90天生存16/18,联合组13/19,标准治疗组6/20。
  • G-CSF组第1、2、3个月改良判别函数评分中位下降分别为60.36%、75.36%、88.73%,对应P=0.02、P=0.05、P=0.00。
  • G-CSF组3个月终末期肝病模型评分中位下降55.77%,P=0.01。

临床怎么用

  • 作者认为G-CSF可改善重型酒精性肝炎患者肝功能并提高生存率,但未发现加用NAC的额外获益。
  • 作者指出这些发现需在更大规模的试验中确认。

局限性

  • 原文指出这些发现需在更大规模的试验中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with alcoholic hepatitis (AH) have high mortality, so new therapies are needed. Administration of granulocyte colony stimulating factor (G-CSF) increases survival times of patients with AH. It is not known whether addition of N-acetyl cysteine (NAC) to G-CSF could further increase survival time. We performed a randomized controlled pilot study to compare the efficacy of standard medical therapy with pentoxifylline to treatment with a combination of G-CSF and standard medical therapy as well as to the combination of NAC, G-CSF, and standard medical therapy in patients with severe AH. METHODS: We performed an open-label, single-center study of 57 patients with severe AH admitted to a Liver Intensive Care unit in India from October 2014 through March 2017. Patients were randomly assigned to groups that received standard medical therapy (with pentoxifylline) plus G-CSF for 5 days (G-CSF group; n = 18), standard medical therapy plus G-CSF and intravenous NAC for 5 days (combination group; n = 19), or standard medical therapy alone (n = 20). Clinical data and blood samples were collected at baseline; on day 6; and 1, 2, and 3 months after the study began. CD34+ cells were measured in blood samples collected on days 0 and 6. The primary outcome was proportion of patients surviving for 90 days. Secondary outcomes were mobilization of CD34+ cells at day 6, as well as Child Turcotte Pugh, model for end-stage liver disease, and modified discriminant function scores until day 90. RESULTS: Significantly higher proportions of patients in the G-CSF group (16/18) and the combination group (13/19) survived for 90 days than in the standard medical therapy group (6/20) (P = .0001 for G-CSF group and P = .037 and combination group). The GGSF and combination groups each had increased numbers of CD34+ cells from baseline until day 6, compared with the standard medical therapy group. The G-CSF group (but not the combination group) had significantly larger median reductions in modified discriminant function scores at study months 1 (reduction of 60.36%), 2 (reduction of 75.36%), and 3 (reduction of 88.73%) vs the standard medical therapy group (P = .02; P = .05; and P = .00, respectively). The G-CSF group had a significantly larger median reduction in model for end-stage liver disease score at 3 months (reduction of 55.77%; P = .01), but not in Child Turcotte Pugh score, compared with the standard medical therapy group. All groups had similar numbers of complications. CONCLUSION: In a pilot randomized controlled trial, we found administration of G-CSF to improve liver function and increase survival times in patients with severe AH, compared with standard therapy. We found no evidence for benefit of adding NAC to G-CSF. These findings require confirmation in larger trials. ClincialTrials.gov, number: NCT02971306.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Singh V, Keisham A, Bhalla A, et al. Efficacy of Granulocyte Colony-Stimulating Factor and N-Acetylcysteine Therapies in Patients With Severe Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2018. PMID: 29391265. doi:10.1016/j.cgh.2018.01.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。